Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Hartford HealthCare selects Glytec’s eGMS for diabetes management

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announced that Hartford HealthCare will deploy the company’s eGlycemic Management System® (eGMS®) across its five hospitals.

eGMS enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

Hartford HealthCare (HHC), well known for quality, complex and innovative care, consists of Hartford Hospital, Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut and Windham Hospital, as well as numerous clinics throughout Connecticut.

Glytec’s unique eGMS will help support HHC’s tradition of patient focus and quality of care by providing access to evidence-based, medical intelligence for patients requiring insulin therapy.

"Glycemic management has long been a priority for our health system, and our results have historically been very good. Our previous efforts have included deploying our own IV insulin dosing decision support tool on a limited basis, but the complexity and costs associated with maintaining and scaling the tool, as well as attempting to add subcutaneous dosing support with the necessary integrations and analytics, were challenging," said Dr. Rocco Orlando III, senior vice president and chief medical officer, Hartford HealthCare.

eGMS provides clinician-developed, algorithm-based software (Glucommander) designed to consider insulin sensitivity, and provide individualized dosing recommendations to address and prevent excursions through all aspects of insulin therapy – including intravenous (IV), transition from IV to subcutaneous (SubQ), SubQ, and pediatric dosing recommendations.

The ongoing performance and impact of HHC’s glycemic control initiative will be measured and monitored through Glytec’s GlucoMetrics. Additionally, GlucoSurveillance will provide near real-time identification of patients in need of glycemic intervention and insulin therapy.

The eGMS will be integrated with HHC’s Cerner and Epic EMRs to allow for a seamless end-user experience. Through the standardization of processes and personalization of treatment, eGMS has been proven to reduce infection rates, length-of-stay, readmissions and resource utilization (clinician time as well as supplies).

"Glytec is collaborating with healthcare providers across the country to establish a new standard of care in glycemic control. Partnering with HHC, a leader in patient care and itself a pioneer in the glycemic management realm, is a natural fit," said Melanie Mabrey, DNP, ACNP-BC, BC-ADM, CDTC, FAANP, vice president of clinical practice, Glytec.